U.S. markets closed

AIkido Pharma Inc. (AIKI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
5.90+0.11 (+1.90%)
At close: 04:00PM EDT
5.89 -0.01 (-0.17%)
After hours: 07:56PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Slow Stochastic

Slow Stochastic

Previous Close5.79
Bid5.88 x 800
Ask5.99 x 1300
Day's Range5.60 - 5.97
52 Week Range4.30 - 17.17
Avg. Volume124,383
Market Cap30.99M
Beta (5Y Monthly)1.56
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateMay 12, 1980
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for AIKI

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • AIkido Pharma Inc.
    Daily – Vickers Top Buyers & Sellers for 05/03/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    last yearArgus Research
View more
  • PR Newswire

    AIkido Pharma Inc. Regains Compliance with NASDAQ Listing Requirements

    AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that on June 23, 2022, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that it has regained compliance with the $1.00 minimum bid price requirement for continued listing on The NASDAQ Capital Market under Listing Rule 5550(a)(2). The Company regained compliance with the NASDAQ's requirements when the closing bid price for the Company's common stock was at o

  • PR Newswire

    AIkido Inc. Announces the Formation of a New Financial Services Subsidiary

    AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") announced the formation of a wholly owned subsidiary with the purpose of making strategic investments and acquisitions across the fintech and financial services industries. The new subsidiary is expected to be the centerpiece of a long-range plan to diversify AIkido's business beyond biotechnology, in order to reduce volatility and mitigate risk while increasing revenue and enhancing shareholder value.

  • GlobeNewswire

    Significant Investor in AIkido Pharma Urges Board to Commit to Sell Assets and Return Capital to Stockholders

    The Board and Management Clearly Have Lost the Confidence of Stockholders Concerned that Allowing the Status Quo to Continue Will Result in More Insider Dealing and Destruction of Stockholder Value Believes the Commencement of an Orderly Process to Sell Company Assets and Return Capital to Stockholders Represents the Best Path Forward to Preserve Stockholder Value NEW YORK, June 21, 2022 (GLOBE NEWSWIRE) -- Shalom Auerbach, a significant stockholder of AIkido Pharma Inc. (NASDAQ: AIKI) beneficia